Answers are grounded in this paper and cite their sources.
BACKGROUND: Optic neuritis associated with aquaporin-4 (AQP4)-immunoglobulin G causes severe visual loss. Although high-dose intravenous methylprednisolone is the standard for acute attacks, barriers including cost and wait times can delay urgent treatment. Similarly, restricted access to high-cost biologics leads to greater reliance on oral corticosteroid maintenance. Therefore, establishing the efficacy of accessible oral steroids is critical to more equitable health care systems. METHODS: Studies of any design reporting outcomes of oral corticosteroid treatment for acute or maintenance therapy in seropositive AQP4-neuromyelitis optica spectrum disorder optic neuritis were included. Medline, Embase, Web of Science, PubMed, Scopus, and Cochrane CENTRAL were searched from inception to July 10, 2025. RESULTS: Thirty-two studies were included (5 acute treatment, 27 maintenance treatment), comprising case reports, case series, and retrospective cohorts. In the acute setting (n = 5 studies), high-dose oral methylprednisolone (1 g/day) was associated with visual recovery, whereas low-dose prednisone monotherapy (e.g., 20 mg/day) resulted in incomplete recovery and early relapse. In the maintenance setting (n = 27 studies), oral corticosteroid monotherapy was associated with high rates of treatment relapse, particularly in pediatric cohorts. Successful tapering was observed primarily when oral steroids were used as a bridge to steroid-sparing immunosuppressants rather than as a standalone long-term strategy. CONCLUSIONS: High-dose oral methylprednisolone is likely a practical and effective alternative to intravenous therapy for acute AQP4-positive optic neuritis, especially in resource-limited settings. Conversely, low-dose oral monotherapy is insufficient for acute rescue or long-term disease control. Clinical management should prioritise high-dose regimens for acute treatment and restrict maintenance steroids to a bridging role during initiation of steroid-sparing agents.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: